Tagged with Access,

Colombia Eduardo Obraczka, managing director at Merck Colombia, shares his appreciation for the flexibility of the Colombian talent pool, while explaining Merck’s successful strategy that has led to the impressive growth of the organization in the country, and highlights how Merck is continuously fostering an innovative and dynamic environment. How does…

Austria Arnoldas Doviltis, general manager of Ferring Austria, a research-driven Swiss biopharmaceutical company, elaborates on the autonomous nature of local Ferring affiliates and how this allows a tailored approach to conduct Austrian operations. Furthermore, he provides an insight into the peculiarities of market access within Austria compared to other European nations…

Austria Wolfgang Jank, general manager and founder, and Tina Theuer, managing partner, of first pharma J.M.T. GmbH, a young Austrian pharmaceutical service company, discuss the challenges of founding a new business and the obstacles companies face when launching products in Austria. They also provide an in-depth analysis of the services they…

Colombia Adriana Forero, General Manager of GSK Colombia, speaks about their efforts to remain at the forefront of the healthcare industry, while keeping their focus on increasing access, innovation and focus on the patient in order to become a strategic partner for the Government and the Colombian healthcare system Ms. Forero,…

Colombia Oscar Fernando Otalora Gomez, Executive Director of HB Human Bioscience, discusses the importance of bringing innovation and technology to the Colombian market, while being committed to providing medication at a reasonable price to save lives. To begin with, could you introduce HB Human Bioscience to our international audience and give…

Indonesia Evie Yulin, biopharma country director at Merck Indonesia, speaks towards the meaning of innovation in emerging countries and how the company engages in innovation beyond products. Since 2012, Merck has been implementing “Fit for 2018” – a transformation program aiming to drive the growth of the company globally. How has this…

Austria Ana Kostova, Austrian country president for AstraZeneca, a global powerhouse in innovative drugs and R&D, discusses the opportunities and challenges of introducing innovative treatments into the Austrian healthcare system as well as AstraZeneca´s exciting pipeline, especially in the field of oncology. She also provides an insight into the future potential…

Singapore Claus Zieler discusses the Asia Pacific region’s importance to Bayer’s global operations, the company’s commitment to increasing its portfolio of innovative medicines, and the potential for innovation coming from Asian markets. Having spent four years in Japan previously, how have you had to adapt to serving the entire Asia Pacific…

USA In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs; double the amount of the mid-year average since 2007. “The eight oncology treatments approved by the FDA this year represent…

Ukraine Natalia Zago, managing director of Takeda Ukraine, one of the leading international companies operating in the country, provides insights into her main priorities to drive the growth of the company under the conditions of significant changes in the pharmaceutical market and Ukrainian healthcare system.   Nobody can deny that Ukraine…

Indonesia Benoit Martineau, President Director at Sanofi Indonesia, explains the transformation of the Indonesian affiliate and reaffirms the strong commitment of Sanofi in helping the Indonesian government to successfully implement their patient access roadmap. Mr. Martineau, could you please introduce yourself to our international audience as well as your main areas…

Austria Dr. Wolfgang Andiel, president of the Austrian Association of Generic Medicines (OeGV, Österreichischer Generikaverband), which acts as a unified voice to represent generics companies in Austria, provides an in-depth analysis of the vicious cycle associated with establishing generics market share in Austria as well as the inconsistences of government regulations…